Chemo plus durvalumab before surgery for stomach cancer
This trial tests adding an immunotherapy drug called durvalumab to two different chemotherapy combinations before surgery for stomach or gastroesophageal junction cancer. The goal is to see if these combinations shrink tumors more effectively and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stomach cancer or gastroesophageal junction cancer that can be surgically removed (not spread to distant organs).
- You have not had any prior cancer treatment for this condition.
- You are in good overall health (able to perform daily activities) and have adequate organ function.
- You have a life expectancy of at least 24 weeks and weigh more than 30 kg.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (FLOT) plus an immunotherapy drug (durvalumab) before and after surgery for stomach or esophageal cancer that can be removed. The goal is to see if adding durvalumab helps improve outcomes.
This trial tests a combination of chemotherapy (DOS) plus an immunotherapy drug (Adebrelimab) given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the treatment shrinks the tumor and improves outcomes.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This trial tests combining chemotherapy (FOLFOX) with an immunotherapy drug (Toripalimab) before and after surgery for a type of stomach cancer called HER2-negative adenocarcinoma of the esophagogastric junction. It may help shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
Hear when a new Resectable Gasrtic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.